Literature DB >> 18953546

[Retinochoroidopathy after intravitreal anti-VEGF treatment].

M Maier1, N Feucht, I Lanzl, P Kook, C P Lohmann.   

Abstract

A 74-year-old man presented with persistent metamorphopsias of the right eye 2 weeks after intravitreal injection of bevacizumab to treat choroidal neovascularization due to exudative age-related macular degeneration. The diagnosis reached was retinochoroiditis as an occult manifestation of sarcoidosis, possibly resulting from an intravitreal injection of bevacizumab. The patient received a prescription for 100 mg Ultralan to be taken daily for 3 days and then tapered in 3 day steps. During the further course no deterioration of the condition was observed.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 18953546     DOI： 10.1007/s00347-008-1839-3

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


  21 in total

Review 1.  [Intravitreal injection. Monitoring to avoid postoperative complications].

Authors:  C H Meyer; F Ziemssen; H Heimann
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059

2.  Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).

Authors:  Jonathan Shahar; Robert L Avery; Gad Heilweil; Adiel Barak; Esther Zemel; Geoffrey P Lewis; Patrick T Johnson; Steven K Fisher; Ido Perlman; Anat Loewenstein
Journal:  Retina       Date:  2006-03       Impact factor: 4.256

3.  Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment.

Authors:  Raj K Maturi; Laura A Bleau; Donald L Wilson
Journal:  Retina       Date:  2006-03       Impact factor: 4.256

Review 4.  [(Side) effects of VEGF inhibition].

Authors:  F Ziemssen; K U Bartz-Schmidt; S Grisanti
Journal:  Ophthalmologe       Date:  2006-06       Impact factor: 1.059

Review 5.  [White dot syndrome].

Authors:  W Göbel
Journal:  Ophthalmologe       Date:  2008-01       Impact factor: 1.059

6.  Longitudinal cohort study of patients with birdshot chorioretinopathy. III. Macular imaging at baseline.

Authors:  Dominique Monnet; Ralph D Levinson; Gary N Holland; Lamine Haddad; Fei Yu; Antoine P Brézin
Journal:  Am J Ophthalmol       Date:  2007-10-18       Impact factor: 5.258

7.  [Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD. Frequency and progress].

Authors:  D Kook; A Wolf; A S Neubauer; C Haritoglou; S G Priglinger; A Kampik; M W Ulbig
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059

8.  Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration.

Authors:  Clement K Chan; Carsten H Meyer; Jeffrey G Gross; Prema Abraham; Asha S D Nuthi; Gregg T Kokame; Steven G Lin; Michael E Rauser; Peter K Kaiser
Journal:  Retina       Date:  2007-06       Impact factor: 4.256

9.  Penetration of bevacizumab through the retina after intravitreal injection in the monkey.

Authors:  Peter Heiduschka; Heike Fietz; Sabine Hofmeister; Sigrid Schultheiss; Andreas F Mack; Swaantje Peters; Focke Ziemssen; Birgit Niggemann; Sylvie Julien; Karl Ulrich Bartz-Schmidt; Ulrich Schraermeyer
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-06       Impact factor: 4.799

10.  Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.

Authors:  M Vaughn Emerson; Andreas K Lauer; Christina J Flaxel; David J Wilson; Peter J Francis; J Timothy Stout; Geoffrey G Emerson; Thomas K Schlesinger; Susan K Nolte; Michael L Klein
Journal:  Retina       Date:  2007 Apr-May       Impact factor: 4.256
View more
  1 in total

1.  Intravitreal injection of the synthetic peptide LyeTx I b, derived from a spider toxin, into the rabbit eye is safe and prevents neovascularization in a chorio-allantoic membrane model.

Authors:  Flavia Rodrigues da Silva; Mayara Rodrigues Brandão de Paiva; Lays Fernanda Nunes Dourado; Rummenigge Oliveira Silva; Carolina Nunes da Silva; Bruna Lopes da Costa; Cibele Rodrigues Toledo; Maria Elena de Lima; Armando da Silva-Cunha
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2018-11-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.